MultiCell Technologies, Inc.
MCET
Rank in Stocks
#34775
MultiCell Technologies, Inc. (MCET) operates as a biopharmaceutical firm,... MultiCell Technologies, Inc. (MCET) operates as a biopharmaceutical firm, primarily focused on the creation of innovative therapeutic agents and research tools. Their efforts are directed towards addressing a range of medical challenges, including neurological conditions, liver ailments, various types of cancer, and applications within interventional cardiology and peripheral vascular health. The company's product pipeline features several key developments: MCT-125: This investigational therapy is currently in Phase II clinical trials, targeting the primary fatigue commonly associated with multiple sclerosis. MCT-465: A preclinical-stage synthetic double-stranded RNA (dsRNA) candidate, designed to act as a powerful immune enhancer for the treatment of solid tumor malignancies. MCT-485: Another dsRNA therapeutic, still in the discovery phase, which demonstrates tumor cytolytic (cell-destroying) properties, intended for use against diverse cancers. Beyond drug candidates, MultiCell Technologies is also progressing the Ideal BioStent, an innovative bioabsorbable stent specifically engineered for use in interventional cardiology and peripheral vessel procedures. The organization maintains licensing agreements with prominent entities such as Corning Incorporated and Pfizer Inc. Established in 1962, the company was previously known as Exten Industries, Inc. before officially changing its name to MultiCell Technologies, Inc. in April 2004. Its corporate headquarters are situated in Woonsocket, Rhode Island.
Share Price
$0.000001
Last synced: 2026-11-09
Market Cap
$5.00K
Change (1 day)
-90.00%
Change (1 year)
-90.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade MultiCell Technologies, Inc. (MCET)
Category
Healthcare
Operating Margin for MultiCell Technologies, Inc. (MCET)
Operating Margin as of November 2026 TTM: -1,465.60%
According to MultiCell Technologies, Inc.'s latest financial reports, its current operating margin (TTM) is -1,465.60%. At the end of 2014 the company had an operating margin of -1,465.60%.
Operating Margin history for MultiCell Technologies, Inc. from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -1,465.60% | 0.00% |
| 2014 | -1,465.60% | -47.16% |
| 2013 | -2,773.89% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.03% |
US
|
|
| -149.01% | -99.90% |
US
|
|
| 25.57% | -100.02% |
AU
|
|
| 31.23% | -100.02% |
BE
|
|
| 29.35% | -100.02% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about MultiCell Technologies, Inc.'s operating margin
What is MultiCell Technologies, Inc.'s operating margin?
MultiCell Technologies, Inc.'s operating margin is -1,465.60%, as of Nov 2026.
What was MultiCell Technologies, Inc.'s operating margin in 2014?
In 2014, MultiCell Technologies, Inc.'s operating margin was -1,465.60%, compared with -2,773.89% in 2013.
How does MultiCell Technologies, Inc.'s operating margin compare with similar companies?
MultiCell Technologies, Inc.'s operating margin (-1,465.60%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.